In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid)

Chemotherapy

Volumn 47, Issue 4, 2001, Pages 243-249

  Ling, T K W ^a   Fung, K S C ^a   Cheng, A F B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

In vitro activity; Post antibiotic effect; Synercid

Indexed keywords

AMPICILLIN; CLARITHROMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; QUINUPRISTIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; DRUG EFFECT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; VIRGINIAMYCIN;

EID: 0034962370     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048530     Document Type: Article

References (24)

1. Molecular epidemiology of multiresistant Staphylococcus epidermidis
2. Antimicrobial resistance in Streptococcus pneumoniae: An overview
3. Statewide surveillance for antibiotic-resistant bacteria - New Jersey
4. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium
5. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium
6. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
7. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria
8. RP59500, a new streptogramin highly active against recent isolates of North American staphylococci
9. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
10. A guide to sensitivity testing
11. Post-antibiotic effect
12. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates
13. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria
14. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
15. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium
16. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae
17. Post-antibiotic effect of the new streptogramin RP 59500
18. Post-antibiotic effects of RP 59500 with Staphylococcus aureus
19. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC
20. Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin/dalfopristin against gram-positive and -negative organisms
21. Pronounced postantibiotic effect of quinupristin-dalfopristin in static cultures of Staphylococcus aureus: An effect not seen with other antibiotics
22. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500